Patents Assigned to Fujisawa Pharmaceuticals Co., Ltd.
-
Publication number: 20050043333Abstract: A quinazolinone derivatives having poly (adenosine 5?-diphospho-ribose) polymerase (PARP) inhibitory activity represented by the formula (I): wherein R1 is substituted cyclic amino groups or optionally substituted amino group, R2 is substituent, n means an integer of 0 to 4, and L1 is (1) cyclo (lower) alkylene, (2) cyclo (lower) alkenylene, (3) diradical of saturated- or unsaturated monocyclic group with one or more nitrogen atom(s), which is obtained after removal of one hydrogen atom from said monocyclic group, or (4) —N(R3)—L2— (wherein R3 is hydrogen or lower alkyl, and L2 is lower alkylene or lower alkenylene), or its prodrug, or a salt thereof.Type: ApplicationFiled: December 19, 2002Publication date: February 24, 2005Applicant: Fujisawa Pharmaceutical Co., LtdInventors: Junya Ishida, Kouji Hattori, Yoshiyuki Kido
-
Publication number: 20050043371Abstract: This invention relates to new aminoalcohol derivatives or salts thereof represented by the following formula [I]: wherein each symbol is as defined in the specification or salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.Type: ApplicationFiled: October 7, 2004Publication date: February 24, 2005Applicant: Fujisawa Pharmaceutical Co. Ltd.Inventors: Kiyoshi Taniguchi, Naoaki Fujii, Minoru Sakurai, Yasuyo Tomishima, Hisashi Takasugi
-
Publication number: 20050027121Abstract: This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.Type: ApplicationFiled: November 24, 2003Publication date: February 3, 2005Applicant: Fujisawa Pharmaceutical Co., Ltd.Inventors: Hiroshi Miyake, Kazuhiko Take, Shinji Shigenaga, Hidenori Azami, Hiroshi Sasaki, Yoshiteru Eikyu, Kazuo Nakai, Junya Ishida, Takashi Manabe, Nobukiyo Konishi, Tadashi Terasaka
-
Publication number: 20050014812Abstract: The present invention provides novel benzimidazole compounds of the formula (I): wherein each symbol is as defined in the specification, salts thereof and prodrugs thereof, which are useful in treating, for example, the diseases curable through decrease in blood sugar level.Type: ApplicationFiled: June 4, 2004Publication date: January 20, 2005Applicants: Fujisawa Pharmaceutical Co., Ltd., Daicel Chemical Industries, Ltd.Inventors: Hisashi Hayashida, Keiko Hatanaka, Takeshi Kato, Yoshiyuki Kido, Masaki Tomishima, Hiroshi Kayakiri, Ichiro Takase, Takahiro Hiramura
-
Publication number: 20050014685Abstract: This invention relates to new lipopeptide compound represented by the following general formula (I): Wherein R1, R2, R3, R4, R5 and R6 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on ?-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.Type: ApplicationFiled: June 23, 2004Publication date: January 20, 2005Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.Inventors: Hiroaki Mizuno, Hiroshi Matsuda, Takahiro Matsuya, David Barrett
-
Publication number: 20050004094Abstract: The present invention relates to a compound of the formula [I]: wherein R1 is lower alkyl which may have suitable substituent(s), R2 is amino, protected amino or guanidino, R3 is carboxy or protected carboxy, R4 is amino or protected amino, and A is lower alkylene, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 28, 2004Publication date: January 6, 2005Applicants: Fujisawa Pharmaceutical Co., Ltd., WAKUNAGA PHARMACEUTICAL CO., LTD.Inventors: Toshio Yamanaka, Hidenori Ohki, Masaru Ohgaki, Shinya Okuda, Ayako Toda, Kohji Kawabata, Satoshi Inoue, Keiji Misumi, Kenji Itoh, Kenji Satoh
-
Publication number: 20050004014Abstract: This invention relates to new lipopeptide compound represented by the following general formula (I): wherein R1, R2, R3, R4 and R5 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on ?-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.Type: ApplicationFiled: June 4, 2004Publication date: January 6, 2005Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.Inventors: Takahiro Matsuya, Hiroaki Mizuno, Takashi Tojo, Hiroshi Matsuda, David Barrett
-
Publication number: 20040266774Abstract: The present invention is a compound and pharmaceutical composition comprising a compound of formula (I): 1Type: ApplicationFiled: June 14, 2004Publication date: December 30, 2004Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.Inventors: Kiyotaka Ito, Glen W. Spears, Fumie Takahashi, Akira Yamada, Masaki Tomishima, Hiroshi Miyake
-
Publication number: 20040259923Abstract: A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.Type: ApplicationFiled: January 27, 2004Publication date: December 23, 2004Applicant: Fujisawa Pharmaceutical Co. Ltd.Inventors: Takayuki Inoue, Takashi Tojo, Masataka Morita, Mitsuru Ohkubo, Kousei Yoshihara, Akira Nagashima
-
Patent number: 6833353Abstract: A new use of immunosuppressant for treating or preventing MMp-medicated diseases is provided. The preferred immunosuppresants are tacrolimus, cyclosporing A or 33-epi-chloro-33-desoxyascomycin (pimecrolimus). Particularly, preferable MMP-mediated diseases are the diseases or conditions caused by gelatinase and/or collagenase, and/or inflammatory diseases concerned with gelatinase; such as arthritis (e.g., osteoarthritis, rheumatoid arthritis, etc.) cerebral diseases (e.g., stroke, etc.), tissue ulceration (e.g., corneal, epidermal and gastriculceration, etc.), abnormal wound healing, periodontal diseases, bone diseases (e.g., Paget's diseases, osteoporosis. etc.), tumor growth, tumor metastasis or invasion, HIV-infection, decubitus, decubitis ulcer, restenosis, epidermolysis bullosa, sepsis, septic shock, neoplasm, psoriasis, neovascularization and multiple sclerosis.Type: GrantFiled: March 14, 2001Date of Patent: December 21, 2004Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Nobuchika Yamamoto, Harumi Yamazaki, Takeshi Ishikawa, Shigeru Johki, Fumihiko Sakai
-
Patent number: 6825200Abstract: The present invention a compound represented by the formula (I): where the structural variables R1-R6 are defined herein.Type: GrantFiled: May 6, 2002Date of Patent: November 30, 2004Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Ichiro Shima, Takehiko Ohkawa, Kazuhiko Ohne, Kentaro Sato, Naoki Ishibashi, Kenichiro Imamura
-
Patent number: 6825003Abstract: The present invention provides a cyclic lipopeptide acylase which may effectively deacylate the acyl side chain of a cyclic lipopeptide compound, specifically FR901379 Substance or its analog thereof shown by the following general formula [I], and a process for production of a cyclic peptide compound which comprises the use of said acylase.Type: GrantFiled: January 18, 2002Date of Patent: November 30, 2004Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Satoshi Ueda, Miho Tanaka, Masami Ezaki, Kazutoshi Sakamoto, Seiji Hashimoto, Nobutaka Oohata, Masaru Tsuboi, Michio Yamashita
-
Patent number: 6826033Abstract: The present invention relates to a compound formula (I) wherein X1 is bond or —O—CH2—, (II) or (III) R1 is hydrogen or an amino protective group, a is phenyl, indolyl or carbazolyl, each of which may be substituted with one or two substituent(s), and B is hydrogen; halogen; lower alkyl; lower alkoxycarbonyl; cyclo(lower)alkyl; or a heterocyclic group, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzyl or phenyl, each of which may be substituted with one or two substituent(s), or a salt thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiures or urinary incontinence.Type: GrantFiled: March 21, 2003Date of Patent: November 30, 2004Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Minoru Sakurai, Kenichi Washizuka, Hitoshi Hamashima, Yasuyo Tomishima, Masashi Imanishi, Yutaka Nakajima, Hiroaki Ohtake, Satoru Kuroda, Masayoshi Murata, Hiroshi Kayakiri, Naoaki Fujii, Kiyoshi Taniguchi
-
Patent number: 6825018Abstract: A gene encoding D-sorbitol dehydrogenase (SLDH); a process for producing SLDH by culturing host cells transformed by an expression vector having the above gene; and a process for processing L-sorbose or 2-keto-L-gulonic acid (2KLGA) by using the above culture. 2KLGA is an important intermediate in the production of L-ascorbic acid. Thus, a process for producing L-ascorbic acid from the 2KLGA obtained by the above process is also provided.Type: GrantFiled: December 21, 2001Date of Patent: November 30, 2004Assignee: Fujisawa Pharmaceutical Co. Ltd.Inventors: Takashi Shibata, Chiyo Ichikawa, Mitsutaka Matsuura, Yuji Noguchi, Yoshimasa Saito, Michio Yamashita, Yoko Takata
-
Publication number: 20040235105Abstract: The present invention provide a gene encoding D-sorbitol dehydrogenase (SLDH), a method for producing SLDH by culture of a host cell transformed with a vector expressing this gene and a method for producing L-sorbose or 2-keto-L-gulonic acid (2KLGA) using the culture. 2KLGA is an important intermediate for the production of L-ascorbic acid. Therefore, the present invention also provides a method for producing L-ascorbic acid from the 2KLGA obtained by the above-mentioned method.Type: ApplicationFiled: May 13, 2004Publication date: November 25, 2004Applicant: Fujisawa Pharmaceutical Co. Ltd.Inventors: Takashi Shibata, Chiyo Ichikawa, Mitsutaka Matsuura, Yuji Noguchi, Yoshimasa Saito, Michio Yamashita, Yoko Takata
-
Publication number: 20040229889Abstract: A compound having the following formula (I): 1Type: ApplicationFiled: January 12, 2004Publication date: November 18, 2004Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.Inventors: Yasuharu Urano, Shigeki Satoh, Naoki Ishibashi, Kazunori Kamijo
-
Patent number: 6812235Abstract: A beta-alanine derivative of the formula (I) wherein R1 is hydrogen atom or an amino protective group; A is a lower alkylene group or a lower alkenylene group; R2 is hydrogen atom or an amino group which may be substituted with an acyl group; R3 is hydrogen atom or an aryl or aralkyl group which may be substituted with one or more of hydroxy and/or lower alkoxy, a moiety represented by the formula (II), which is a bivalent N-containing 6- to 8-membered heterocyclic group, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 2, 2002Date of Patent: November 2, 2004Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Mitsuru Ohkubo, Satoru Kuroda, Hideko Nakamura, Masatoshi Minagawa, Toshiaki Aoki, Kayoko Harada, Jiro Seki
-
Publication number: 20040214218Abstract: A novel means for DNA compaction is provided.Type: ApplicationFiled: May 17, 2004Publication date: October 28, 2004Applicants: Fujisawa Pharmaceutical Co., Ltd., Eiichi NAKAMURAInventors: Eiichi Nakamura, Masaya Sawamura, Hiroyuki Isobe
-
Publication number: 20040180947Abstract: A sulfonamide compound of the formula (I):Type: ApplicationFiled: March 30, 2004Publication date: September 16, 2004Applicant: Fujisawa Pharmaceutical Co., Ltd.Inventors: Hiroshi Kayakiri, Yoshito Abe, Hitoshi Hamashima, Hitoshi Sawada, Tsuyoshi Mizutani, Teruo Oku, Noritsugu Yamasaki, Osamu Onomura, Masahiro Nishikawa, Takahiro Hiramura, Takafumi Imoto
-
Patent number: 6787543Abstract: A compound of the formula (I): in which Z, R1, R2, R8, R10, R11, R12, R13 and R14 are each as defined in the description, or a salt thereof. The object compound of the present invention has pharmacological activities such as Tachykinin antagonism, and is useful for manufacture of a medicament for treating or preventing Tachykinin-mediated diseases.Type: GrantFiled: December 20, 2002Date of Patent: September 7, 2004Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Kazuhiko Take, Chiyoshi Kasahara, Shinji Shigenaga, Hidenori Azami, Yoshiteru Eikyu, Kazuo Nakai, Masataka Morita